Skip to content
  • About
    • Supporter
    • Expert Index
    • Editorial Board
    • Editorial Team
    • Editorial Policy
  • Contact
  • Sign up

Visit

vjdementia
VJNeurology
Logo
  • Home (current)
  • Diseases
    Parkinson's Disease
    Multiple Sclerosis and Related Disorders
    Headache
    Amyotrophic Lateral Sclerosis
    Epilepsy
    Sleep Disorders
    Stroke
    Neuromuscular Disorders
    Movement Disorders
    View all Diseases
  • Topics
    Biology
    Diagnostics
    Trial Updates
    Treatment
    Prevention
    Surgery
    Imaging
    Genetics
    COVID-19
    View all Topics
  • Conferences
    CONy 2023
    ACTRIMS 2023
    ISC 2023
    EHC 2022
    AES 2022
    WSC 2022
    View all Conferences
  • Features
  • Podcasts
    • About
      • Supporter
      • Expert Index
      • Editorial Board
      • Editorial Team
      • Editorial Policy
    • Contact
    • Sign up

Messoud Ashina

The burden of migraine: from  individuals to society 2:43
The burden of migraine: from individuals to society
Messoud Ashina • 23 Jun 2022
Anti-CGRP monoclonal antibodies for difficult to treat migraines: DELIVER trial 1:47
Anti-CGRP monoclonal antibodies for difficult to treat migraines: DELIVER trial
Messoud Ashina • 23 Jun 2022
PACAP as a future target for anti-migraine medication 3:04
PACAP as a future target for anti-migraine medication
Messoud Ashina • 23 Jun 2022
Real-world studies show effectiveness of anti-CGRP mAbs in difficult to treat patients with migraine 3:19
Real-world studies show effectiveness of anti-CGRP mAbs in difficult to treat patients with migraine
Messoud Ashina • 23 Jun 2022
Latest guidelines on anti-CGRP antibodies: first-line and long-term use 2:24
Latest guidelines on anti-CGRP antibodies: first-line and long-term use
Messoud Ashina • 23 Jun 2022
BKCa channels: potential novel anti-migraine target 4:14
BKCa channels: potential novel anti-migraine target
Messoud Ashina • 29 May 2020
PROMISE-1: eptinezumab in episodic migraine 2:44
PROMISE-1: eptinezumab in episodic migraine
Messoud Ashina • 29 May 2020
The evolving migraine prevention landscape: EAN 2020 highlights 3:29
The evolving migraine prevention landscape: EAN 2020 highlights
Messoud Ashina • 29 May 2020
PEARL study: fremanezumab for chronic or episodic migraine in the real world 3:16
PEARL study: fremanezumab for chronic or episodic migraine in the real world
Messoud Ashina • 29 May 2020
Journal Pages
  • Diseases
  • Topics
  • Medicines
  • Trials
  • Conferences
  • Features
Newsletter

Receive the latest news and videos from VJNeurology via email

Sign up
Contact Us

Contact us for more information

mmp logo

Magdalen Centre
The Oxford Science Park
Oxford OX4 4GA, United Kingdom

VJNeurology logo
The content of VJNeurology is intended for healthcare professionals
  • Cookie Policy
  • Privacy Policy
  • Terms of Use
  • Editorial Policy